Abiopharma

🔍 Bernstein Harold (Executive)

Company: Maze Therapeutics, Inc. (MAZE)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 16,142 shares of Common Stock at $10.42 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,142.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,142 shares of Common Stock at $27.6063 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 16,142 shares of Stock Option (Right to Buy) at $10.42 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2032-10-26 | equity_swap_involved: 0 | shares_owned_after: 176,803.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $28.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.